Welcome to our dedicated page for Lunai Bioworks news (Ticker: LNAI), a resource for investors and traders seeking the latest updates and insights on Lunai Bioworks stock.
Lunai Bioworks Inc. (NASDAQ: LNAI) generates news at the intersection of AI-powered drug discovery, cancer immunotherapy, neurology, and biodefense. Company announcements and media coverage highlight its use of advanced machine learning, generative biology, and proprietary neurotoxicity datasets to advance therapeutic programs and security-focused research.
Recent news releases describe preclinical breakthroughs in allogeneic dendritic cell therapy for pancreatic cancer, where Lunai reports complete regression of primary and metastatic tumors in humanized mouse models using a second-generation clinical-compliant construct. The company has also announced a first letter of intent to license this immune cell therapy, peer-reviewed publications in journals such as Vaccines, and regulatory interactions supporting potential clinical translation.
Lunai-related news also covers its Augusta platform and the work of its subsidiary BioSymetrics in neurodegenerative and neuromuscular diseases. Updates include identification of Parkinson's disease subtypes and progression-linked targets using PPMI data, multimodal AI models for Alzheimer's disease diagnostics, and participation in a Nature Communications study on serum biomarkers in Duchenne muscular dystrophy. These stories emphasize biomarker discovery, precision stratification, and collaborations with academic and industry partners.
On the biodefense side, Lunai has issued news about AI and zebrafish-based platforms for detecting acetylcholinesterase-interacting compounds relevant to neurotoxicity and potential chemical threats. Corporate and capital markets updates, such as rebranding from Renovaro Inc. to Lunai Bioworks, adoption of the LNAI ticker, reverse stock split, Nasdaq compliance, and private placements, also appear in the news flow. Investors and observers can use this page to follow scientific milestones, partnership discussions, regulatory updates, and financing events related to Lunai Bioworks.
Lunai Bioworks (NASDAQ: LNAI) subsidiary BioSymetrics signed a non-binding LOI with Geneial to convert patient-led rare neurological datasets into trial-ready cohorts and pursue commercial pharma partnerships. Initial programs will integrate longitudinal registry data to identify patient subgroups and enable cohort activation for translational and clinical development.
Lunai Bioworks (NASDAQ: LNAI) announced a revenue-generating, multi-year defense collaboration through its subsidiary BioSymetrics to deploy an AI-enabled platform for chemical threat assessment.
The program integrates in vivo zebrafish phenotypic screening with AI-driven mechanism-of-action prediction, targets neuroactive and neurotoxic compounds, and can screen hundreds to thousands of compounds per week while additional engagements are under discussion.
Lunai Bioworks (NASDAQ: LNAI) executed a binding $20.0 million strategic transaction to acquire a blood-brain barrier delivery platform and CNS Alzheimer's drug assets from Clemann Group, structured as Series B Convertible Preferred at a fixed conversion price of $1.50 per share with a 19.9% beneficial ownership limitation.
The deal contains no variable pricing or resets and is described as NASDAQ compliant. The platform enables compounds to cross the BBB, activate selectively in the brain, and targets pathways tied to acetylcholinesterase modulation, strengthening Lunai's CNS Alzheimer’s pipeline and broader CNS development capabilities.
Lunai Bioworks (NASDAQ: LNAI) launched the Pathfinder Consortium on March 19, 2026, a national academic–industry alliance to accelerate chemical countermeasure discovery and federal stockpiling.
The consortium aims to compress countermeasure development to ~36 months and target U.S. procurement programs sized between $400M and $1.2B per program, leveraging BioSymetrics' AI phenotypic platform and multi‑partner execution.
Lunai Bioworks (NASDAQ: LNAI) announced issuance of U.S. Patent No. 12,369,861 on Feb 19, 2026 for "Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions."
The patent covers Lunai's foundational multimodal data standardization and bias-removal layer used before predictive AI modeling, intended to improve biomarker discovery, disease subtyping, and gene network mapping across CNS, oncology, and biodefense programs.
Lunai Bioworks (NASDAQ: LNAI) was featured on CNBC Business Minute on Feb 13, 2026. CEO David Weinstein described the company’s proprietary AI platform for accelerating therapeutic discovery in CNS disorders and strengthening biodefense preparedness.
The platform integrates multimodal biological datasets, advanced machine learning, and in vivo validation to identify targets, optimize candidates, and compress development timelines. The company said it is advancing discussions with pharmaceutical firms and government agencies about its biotech and biodefense capabilities.
Lunai Bioworks (NASDAQ:LNAI) says its Augusta AI platform is now commercial after 12 months of development and is in active negotiations with pharmaceutical and drug‑discovery partners. The company highlights three revenue engines: AI drug discovery (CNS and new oncology pilot), AI biodefense programs targeting government contracts, and an allogeneic dendritic cell immunotherapy with published preclinical tumor regressions and an LOI for licensing.
The release emphasizes faster target validation via high‑throughput in vivo testing, near‑term pilots that can expand to commercial relationships, and ongoing efforts to finalize biodefense funding and a pharma royalty partnership.
Lunai Bioworks (NASDAQ: LNAI) launched an AI oncology pilot on Feb 9, 2026 to analyze randomized Phase 2 metastatic colorectal cancer trial data with a clinical-stage partner. The pilot uses Lunai's Augusta AI platform to evaluate de-identified patient-level clinical, imaging, and longitudinal outcomes focusing on overall survival and disease progression.
The goal is to define biologically meaningful patient subgroups to inform FDA trial design, optimized inclusion criteria, endpoint strategy, and statistical powering, with potential expansion to multi-study commercial programs and other tumor types if data support it.
Lunai Bioworks (NASDAQ: LNAI) launched Sentinel, a transformer-based AI safeguard that embeds inside large language and scientific foundation models to screen and block generation of novel chemical threat agents in real time. Sentinel combines Lunai's chemical foundation model trained on ~550 million public chemical structures and fine-tuned with the company's proprietary in-vivo toxicology and phenotypic datasets to detect latent toxic signatures and mechanisms, including neurotoxic and cytotoxic patterns. The product is positioned as part of a three-program biodefense strategy alongside Pathfinder and Counteract and targets AI developers, government agencies, and life-science platforms seeking integrated molecular-level biosecurity.
Lunai Bioworks (NASDAQ: LNAI) completed an NIH STTR commercial milestone creating high-resolution, multidimensional behavioral signatures of ethanol exposure and withdrawal and has launched a commercial Alcohol Use Disorder (AUD) drug-discovery program.
The program uses scalable high-throughput vertebrate screening, targets underexplored mechanisms, is supported by NIH funding, and is run in collaboration with Dr. Calum MacRae at Brigham and Women's Hospital/Harvard Medical School.
Company cites a large unmet need: ~30 million U.S. individuals affected, ~95% receiving no effective pharmacologic treatment, and a ~$250 billion annual economic cost.